Infectious bronchitis in laying hens: the relationship between haemagglutination inhibition antibody levels and resistance to experimental challenge.
In three separate and unrelated experiments, in which vaccinated hens were challenged with virulent infectious bronchitis virus, the ability of individual hens to maintain egg production was related to their serum haemagglutination inhibition antibody titre at the time of challenge. It was found that, regardless of the vaccination programme used, the ability of laying hens to withstand infectious bronchitis virus challenge, as measured by the effect upon their egg production, is directly related to individual antibody titre at the time of challenge. In all three experiments, birds with antibody titres of >/=8 Iog2 (n = 82) did not show a significant reduction in egg production after challenge while those with titres within the range 5-7 log(2) inclusive (n = 126), over a period of 3 or 4 weeks after challenge, showed a significant reduction in their rate of egg lay, viz: 0.38, 0.33 and 0.47 eggs per hen per week, respectively and those with titres <4 log(2) (n = 101) showed, over the same time period, a reduction of 1.0, 0.45 and 1.16 eggs per hen per week, respectively. The ability of different vaccination programmes to stimulate uniformly high antibody responses to infectious bronchitis virus, and hence good overall protection of egg production was compared. It is concluded that the programme of choice is first to vaccinate the birds with a highly attenuated strain of live infectious bronchitis vaccine during rearing (H120), followed by the injection of a potent killed oil emulsion adjuvant vaccine at point-of-lay. The ability of the less attenuated H52 strain of live infectious bronchitis vaccine to interfere with response to killed vaccine was demonstrated in two of the three experiments. In both cases this interference was accompanied by an increased susceptibility of the hens to the effect of infectious bronchitis virus challenge on egg production.
Box
P G
PG
Glaxo Animal Health Limited, Middlesex, England.
Holmes
H C
HC
Finney
P M
PM
Froymann
R
R